Ndembi N, Lyagoba F, Nanteza B, Kushemererwa G, Serwanga J, Katongole-Mbidde E, Grosskurth H, Kaleebu P
MRC/UVR1/Uganda Research Unit on AIDS, Entebbe, Uganda.
AIDS Res Hum Retroviruses. 2008 Jun;24(6):889-95. doi: 10.1089/aid.2007.0317.
To evaluate transmitted HIV-1 drug resistance and study the natural polymorphism in pol of HIV-1 strains of newly diagnosed women attending an antenatal clinic in Uganda we sequenced the protease and reverse transcriptase genes for 46 HIV-1 strains from the threshold surveillance. Of the 46 sequences analyzed, 48.0% were subtype A1 (n 22), 39.0% subtype D (n 18), 2.0% subtype A2 (n 1), 2.0% subtype C (n 1), and 9.0% intersubtype recombinant A1/D (n 4). Overall, many minor mutations were identified in the protease sequences. None of the strains had major associated mutations to any RTI drug or drug class interest after genotyping 37 samples of our cohort. The HIV drug resistance prevalence estimate in Entebbe following the HIVDR-TS methodology is less than 5% as set out by WHO guidelines.
为评估传播的HIV-1耐药性，并研究乌干达一家产前诊所新诊断女性中HIV-1毒株pol基因的自然多态性，我们对阈值监测中的46株HIV-1毒株的蛋白酶和逆转录酶基因进行了测序。在分析的46个序列中，48.0%为A1亚型（n = 22），39.0%为D亚型（n = 18），2.0%为A2亚型（n = 1），2.0%为C亚型（n = 1），9.0%为A1/D亚型间重组体（n = 4）。总体而言，在蛋白酶序列中鉴定出许多小突变。在对我们队列中的37个样本进行基因分型后，没有菌株对任何感兴趣的RTI药物或药物类别有主要相关突变。按照HIVDR-TS方法，恩德培的HIV耐药性流行率估计低于世卫组织指南规定的5%。
